119 Results
Sort By:
Published on January 13, 2023
Newly identified markers of atherosclerotic coronary artery disease (ASCAD) were pinpointed in a study using digital twins. The work was carried out by multi-omics specialist G3 Therapeutics and AI company Aitia, which has Gemini Digital Twin technology. These new findings suggest triglyceride-rich LDL particles could be a novel diagnostic marker…
Published on July 7, 2022
Researchers have used custom-made kidney organoids to uncover which cells cause tumors in patients with tuberous sclerosis complex (TSC). They found that kidney tumors in these patients start in Schwann cell precursors. In addition, they determined a single mutation in one of the key genes affected in the disease (TSC1…
Published on March 21, 2024
California-based healthcare company SEQSTER has been chosen to drive forward a ground-breaking U.S. research network that aims to improve the care of people with multiple sclerosis (MS). The company will apply its cutting-edge data sharing platform and longitudinal patient records system to the MS Implementation Network (MSIN), which was set…
Published on January 11, 2024
Ancient genes predisposing people to multiple sclerosis (MS) may have spread due to the protection they afforded against infectious diseases thousands of years ago. A major migration of sheep and cattle herders 5000 years ago appears to have introduced genes that increased the risk of MS into northern Europe, where…
Published on November 28, 2023
A stem cell-based treatment for progressive multiple sclerosis (MS) achieved good results in a Phase I trial led by researchers at the University of Cambridge and the University of Milan Bicocca. Almost one million people in the U.S. have MS, with around 200 new cases diagnosed every week. It is…
Published on September 26, 2023
New research led by investigators at Uppsala University in Sweden shows emerging evidence that autologous hematopoietic stem cell transplantation (aHSCT) may be a suitable treatment for relapsing-remitting multiple sclerosis (MS). Relapsing-remitting MS (RRMS) is characterized by distinct inflammatory episodes that result in varying degrees of disability. The symptoms will resolve…
Published on December 2, 2022
Buoyed by a recent proof-of-concept trial of its cytoxic T lymphocytes (CTL) targeting treatment of SARS-CoV-2 infection, late stage biopharma Tevogen Bio announced will begin work to study potential therapeutic use of its allogeneic genetically unmodified precision T cell technology in multiple sclerosis (MS) by developing Epstein-Barr virus (EBV) specific…
Published on January 6, 2022
The largest and most thorough high-resolution microglial genomic atlas of its kind has been created by scientists at the Icahn School of Medicine at Mount Sinai. Their results, published in Nature Genetics, support the idea that microglia may play critical roles in some cases of brain disease, including Alzheimer’s disease, Parkinson’s…
Published on November 11, 2021
A study led by researchers at Vanderbilt University Medical Center has identified a potential new drug target to treat inflammatory conditions such as multiple sclerosis, inflammatory bowel disease, and allergies, a mitochondrial enzyme encoded by the gene MTHFD2. This enzyme has previously been linked to cancer and is involved in…
Published on October 20, 2020
New research suggests that antibiotic or probiotic strategies that may be developed to help prevent or treat multiple sclerosis (MS) should take into account host genetics, the pre-existing gut microbiome, and the timing or mode of the intervention. This is the conclusion of a team of investigators from the University…
Published on April 15, 2019
DNAnexus, UPMC, and Sutter Health network said today they have launched a large-scale clinico-genomic multiple sclerosis (MS) research study aimed at improving personalized treatments for people with the group of 30+ inherited neuromuscular diseases. Under the collaboration, whose value was not disclosed, researchers at the Sutter Health Center for Precision…
Published on March 8, 2019
Genomics Medicine Ireland (GMI) and University College Dublin (UCD) said they will partner to examine the relationship between genetic variation and human disease in up to 10% of the Irish population. GMI—which recently became the Irish subsidiary of WuXi NextCode—and UCD said their partnership would be one of the largest…
Published on March 27, 2024
Continuing a trend, yesterday AbbVie announced it will acquire Landos, a clinical-stage biotech focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action…
Published on February 28, 2024
A stunning response to CAR T therapy by patients with autoimmune disease was seen in a small study led by a group of German researchers. The use of CAR T in autoimmune diseases has been slowly ramping up over the last few years and this is one of the most…
Published on February 12, 2024
ol.custom-marker { counter-reset: list;}ol.custom-marker > li { list-style: none; counter-increment: list;}ol.custom-marker.parens-after.decimal > li::marker { content: counter(list) “)\a0”;} By Michael N. Liebman Biology embraces the existence of a central dogma, i.e., DNA → RNA → protein, and drug development has embraced its own, i.e., disease → target → drug, but both…